PANews reported on March 21 that according to CoinDesk, ATAI Life Sciences, a listed biopharmaceutical company, announced that it would adopt a Bitcoin financial strategy and planned to initially invest $5 million in Bitcoin. Affected by the news, ATAI's stock price rose briefly.

The company's chairman, Christian Angermayer, said the company initially plans to invest $5 million in Bitcoin, while retaining enough cash, short-term securities and public equity to ensure the company's operating funds until 2027.